Gefitinib vs Rituximab

Gefitinib vs Rituximab: Overview

This comparison examines the pharmacological differences between Gefitinib and Rituximab.

Mechanism of Action

Gefitinib: Selective reversible inhibitor of EGFR tyrosine kinase.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Gefitinib — 48 hours; Rituximab — 22 days.

Chemical Properties

Molecular Formula: Gefitinib — C22H24ClFN4O3.

Molecular Weight: Gefitinib — 446.9000 g/mol.

Type: Gefitinib — Small molecule; Rituximab — Antibody.